Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: Analysis of 126 patients

British Journal of Cancer

Volumn 90, Issue 5, 2004, Pages 968-974

  Ezzat, A A ^a   Ibrahim, E M ^a   Ajarim, D S ^a   Rahal, M M ^a   Raja, M A ^a   Tulbah, A M ^a   Al Malik, O A ^a   Al Shabanah, M ^a   Sorbris, R ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Breast cancer; Chemotherapy; Cisplatin; Locally advanced; Neoadjuvant; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; BREAST SURGERY; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; EXTRAVASATION; FATIGUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; OUTCOMES RESEARCH; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SEIZURE; TREATMENT PLANNING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1942424876     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601616     Document Type: Article

References (40)

1. Anderson ED, Forrest AP, Hawkins RA, Anderson TJ, Leonard RC, Chetty U (1991) Primary systemic therapy for operable breast cancer. Br J Cancer 63: 561-566
2. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Tereniziani M, Zambetti M (1998) Primary chemotherapy in operable breast cancer. Eight-year experience at Milan Cancer Institute. J Clin Oncol 16: 93-100
3. Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38: 29-41
4. Bruckman J, Harris J, Levene M, Chaffey JT, Hellman S (1979) Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer 43: 985-993
5. Comella G, Comella P, Scanni A, Apicella G, D'Aiuto G, Thomas R, Capasso I, DiBonito I, Piccolo S, Carteni G, Gravina A, Frasci G (1998) Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer. A phase I study. Proc Am Soc Clin Oncol 17: 510 (abstract)
6. Cox DR, Oakes D (1997) Regression models and life tables (with discussion). J R Statist Soc B 34: 187-220
7. Cox DR, Snell EJ (1989) Analysis of Binary Data. London: Chapman & Hall
8. De Lena M, Varini M, Zucali R, Viganotti G, Valaguss P, Veronesi U, Bonadonna G (1981) Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 4: 229-236
9. Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Stuart RK, Tulbah AM, Kandil A, Al-Malik OA, Bazarbashi SM (2000) High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat 62: 237-244
10. Ezzat A, Raja MA, Berry J, Bazarbashi S, Zwann F, Rahal M, El-Warith A (1997) A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer. Ann Oncol 8: 663-667
11. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR (1986) Pathological assessment to induction chemotherapy in breast cancer. Cancer Res 46: 2578-2581
12. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685
13. Fleiss JL (1981) Statistical Methods for Rates and Proportions, 2nd edn. New York: Macmillan
14. Haagensen CD, Stout AP (1943) Carcinoma of the breast: criteria of inoperability. Ann Surg 118: 859-870
15. Harmanek P, Sobin LH (1987) TNM Classification of Malignant Tumors, UICC International Union Against Cancer. Berlin, Germany: Springer-Verlag
16. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Marino S, Ingle JN, Cooper MR, Canellos G, Borden E, Fleming G, Holland JF, Graziano S, Carpenter J, Muss H, Norton L (1998) Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17: 390a (abstract)
17. Hortobagyi GN (1997) Paclitaxel-based combination chemotherapy for breast cancer. Oncology 11(3 Supp 2): 29-37
18. Hortobagyi GN, Ames FC, Buzdar QU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62: 2507-2516
19. Hosmer DW, Lemeshow S (1980) Goodness-of-fit tests for the multiple logistic regression model. Commun Statist - Part A Theor Meth A9(10): 1043-1069
20. Kalbfleisch JD, Prentice RL (1980) The Statistical Analysis of Failure Time Data. New York: Wiley
21. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481
22. Kay R (1977) Proportional hazard regression models and the analysis of censored survival data. Appl Statist 26: 227-237
23. Kourousis C, Kakolyris S, Androulakis N, Heras P, Vlchonicolis J, Vamvakas L, Vlata M, Hatzidaki D, Samonis G, Georgoulias V (1998) Salvage therapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. Am J Clin Oncol 21: 226-232
24. Kuerer H, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Sing G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469
25. Lau DH, Young L, Xue L (1998) Paclitaxel: an angiogenesis antagonist in metastatic breast cancer model. Proc Am Soc Clin Oncol 17: 414 (abstract)
26. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
27. Marubini E, Valsecchi MG (1995) Analysing Data from Clinical Trials and Observational Studies. New York: John Wiley and Sons
28. Perez EA, Suman VJ, Krook JE, Stella PJ, Hartman LC, Hatfield AK, Fitch T, Ingle JN (1998) Phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast cancer (MBC): a north central cancer treatment group trial. Proc Am Soc Clin Oncol 17: 635 (abstract)
29. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D (1995) Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547-552
30. Prentice RL (1976) A generalization of the probit and logit methods for dose response curves. Biometrics 32: 761-867
31. Ray-Coquard I, Biron I, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY (1998) Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline-and/or paclitaxel-containing regimens. Cancer 82: 134-140
32. Scholl SM, Foourquet A, Asselian B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc P (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors too large for breast conservative surgery: preliminary results of a randomized trial. Eur J Cancer 30A: 645-652
33. Smith IE, Al-Moundhri M (1998) Primary chemotherapy in breast cancer. Biomed Pharmacother 52: 116-121
34. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks N, Baum M (1993) Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29A: 1796-1799
35. Smith IE, Walsh G, Jones A, Prendivilli J, Johnston PJ, Ramage F, Robertshaw H, Sacks N, Ebbs S (1995) High complete remissions with primary (neoadjuvant) infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429
36. Valagussa P, Zambetti M, Bonadonna G, Zucali R, Mezzanotte G, Veronesi U (1990) Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat 15: 137-147
37. Volm M, Formenti S, Symmans F, Downey A, Muggia F (1998) Neo-adjuvant paclitaxel for locally advanced breast cancer (LABC): preliminary results. Proc Am Soc Clin Oncol 17: 695 (abstract)
38. von Minckwitz G, Dan Costa S, Eiermann W, Blohmer J, Tulusan AH, Jackish C, Kaufmann M (1999) Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17: 1999-2005
39. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from the National Surgical Adjuvant Breast and Bowel Project B-18. J Nat Cancer Inst Monogr 30: 96-102
40. Zucali R, Uslemghi C, Kenda R, Bonadonna G (1976) Natural history and survival of inoperable breast cancer treated with radiotherapy followed by radical mastectomy. Cancer 37: 1422-1431